Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 18, 2010. The filing discloses an amendment to the employment agreement of Eric I. Richman, who was appointed President and interim Chief Executive Officer effective May 2, 2010.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- Base Salary: $350,000 annually (effective May 2, 2010).
- Annual Cash Bonus: Up to 60% of base salary for fiscal year 2010 based on corporate objectives; subsequent years determined by the Compensation Committee.
- Contingent Bonus: Additional 60% of base salary if Mr. Richman is not named Chief Executive Officer during his employment.
- Equity Grant: Option to purchase 100,000 shares of common stock at an exercise price of $1.48 per share.
Material Changes
The primary material change is the formalization of Mr. Richman's interim leadership role and the associated compensation package. Key changes include:
- Establishment of a specific base salary and bonus structure for the interim CEO role.
- Granting of a stock option with a 10-year term, vesting in full on May 2, 2011.
- Implementation of "change in control" and "successor CEO" provisions that trigger immediate vesting of equity awards under specific conditions.
Outlook, Risks, and Contingencies
Management Commentary and Risks: The agreement includes significant contingencies tied to the company's leadership stability and potential acquisition.
- Severance: If terminated without cause or resigns for good reason, Mr. Richman is entitled to 12 months of base salary, 12 months of COBRA coverage, and accelerated vesting of equity awards.
- Successor CEO Trigger: If a permanent CEO is appointed other than Mr. Richman, all unvested equity that would have vested in the following 12 months immediately vests.
- Change in Control: In the event of a change in control followed by a termination without cause or for good reason within three months, all unvested equity immediately vests.
- Release Requirement: Severance and accelerated vesting are contingent upon Mr. Richman executing a general release within 45 days of termination.
Investor Verification Checklist
- Verify the exact terms of the "good reason" and "cause" definitions in the full employment agreement (Exhibit 10.30.3).
- Confirm the current status of the search for a permanent Chief Executive Officer.
- Review the company's cash position to assess the ability to fund the potential 12-month severance obligation ($350,000) if triggered.
- Check the dilution impact of the 100,000 share option grant relative to the total outstanding shares.